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Abstract: The joint statement by the American Thoracic Society, Centers for Disease Control 
and Prevention, and Infectious Diseases Society of America recommends that all patients with 
tuberculosis (TB) undergo testing for human immunodeficiency virus (HIV) infection after 
counseling. In this study, we investigated the prevalence of HIV infection among 120 patients 
diagnosed with microbiologically proven TB aged 18 to 54 years with a mean age of 39.5 years 
(standard deviation 6.75). The subjects studied were 36 male (30%) and 84 females (70%). 
Enzyme-linked immunosorbent assay methods were used to screen for HIV infection among 
the subjects. Of the 120 TB patients tested 30 (25%) were positive for HIV infection. The 
prevalence of HIV was higher in females 24 (80%) compared to males 6 (20%) and among 
singles (66.7%) compared to married subjects (33.3%) (χ2 = 83.5 and χ2 = 126.2, respectively 
P = 0.001). HIV-1 was the predominant viral subtype. HIV prevalence was significantly higher 
in subjects in the 38–47 year and 28–37 year age groups (both 40%) followed by the 18–28 year 
age group (20%) (χ2 = 42.6, P = 0.05). The mean CD4 lymphocyte count of the HIV-infected 
TB subjects was significantly lower (195 ± 40.5 cells/µL) compared to the non-HIV infected 
(288 ± 35.25 cells/µL P = 0.01). This study has shown a high prevalence of HIV among TB 
patients. Reactivation of TB among people living with HIV can be reduced by TB preventive 
therapy and by universal access to antiretroviral therapy.
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Introduction
Tuberculosis (TB) and human immunodeficiency virus (HIV) have been closely 
linked since the emergence of acquired immunodeficiency syndrome (AIDS). HIV 
infection has contributed to a significant increase in the worldwide incidence of 
TB.1,2 By producing a progressive decline in cell-mediated immunity, HIV alters the 
pathogenesis of TB, greatly increasing the risk of developing the disease in co-infected 
individuals, leading to more frequent extrapulmonary involvement and atypical 
radiographic manifestations. Although HIV-related TB is treatable and preventable, 
incidence rates continue to climb in developing nations where HIV infection and TB are 
endemic and resources are limited. Worldwide, TB is the most common opportunistic 
infection affecting HIV seropositive individuals,1 and it is the most common cause of 
death in patients with AIDS.3 The prevalence of HIV infection among TB patients in 
several African countries ranges from 20% to 60%.1 The World Health Organization 
(WHO) estimates that about 8 million new cases of TB and nearly 2 million deaths 
from the disease occur each year.4 Approximately 10 million people are estimated HIV/AIDS - Research and Palliative Care 2010:2 
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to be coinfected with TB and HIV , and over 90% of these 
dually infected individuals reside in developing nations. 
In some areas of sub-Saharan Africa, the rates of coinfec-
tion exceed 1,000 per 100,000 populations.5 Worldwide, 
a similar change has occurred in some developed countries. 
The HIV epidemic has increased the global TB burden and 
focused attention on the need to strengthen links between 
TB and HIV/AIDS program. In response to these health 
emergencies, the WHO has developed an expanded strategy 
aimed at reducing the burden of HIV-related TB infection 
through close collaboration between TB and HIV/AIDS 
programmes. Infection with HIV is the most well known risk 
factor for the development of TB. Because of the prevalence 
of TB amongst HIV-infected patients the joint statement by 
the American Thoracic Society, Centers for Disease Control 
and Prevention, and Infectious Diseases Society of America 
recommends that all patients with TB undergo testing for 
HIV infection after counseling.6,7 The aim of this study was 
to evaluate the prevalence of retroviral infection among TB 
infected and previously undiagnosed HIV patients in Port 
Harcourt Nigeria.
Material and methods
Subjects
A total of 120 patients with microbiologically confirmed 
pulmonary TB attending the Niger hospital chest clinic 
(situated in Diobu, Port Harcourt, Nigeria) were consecutively 
recruited for this study between July and August 2006. The 
diagnosis of TB in the chest clinic is based on patients pro-
viding 3 sputum specimens on 3 consecutive days, examined 
for acid fast bacilli (AFB) and cultured for mycobacterium. 
Culture of mycobacterium is a much more sensitive test 
than smear examination and has been estimated to detect 
10–100 viable microbacteria per mL of sample, and in cases 
of active disease they are found to be 81% sensitive and 
98.5% specific.8 Inclusion criteria included microbiological 
confirmation of pulmonary TB, age 18 years. Written 
informed consent was obtained from all study subjects. 
Pre- and post- test counseling was offered to all test subjects. 
Subjects were made up of 36 men and 84 women with age 
range 18–54 years and mean age of 39.5 years (standard devia-
tion 6.75). Ethical approval was obtained from the Department 
of Medical Laboratory Science, University of Science and 
Technology Institutional Review Board, (Port Harcourt).
Sample collection/preparation
Six mL of venous blood was collected from each patient. 
Three mL were poured into a sterile gel tube without 
anti-coagulant and 3 mL into a second EDTA anticoagulated 
tube. The blood in the gel tubes was allowed to clot, after 
which it was centrifuged for 10 minutes to separate the 
serum from the clotted cells. Sera from all patients were then 
screened for the presence of HIV antibodies: using the WHO 
recommended strategy for HIV antibody testing using two 
kit methods. The HIV screening was undertaken using the 
Abbott Determine HIV 1 an enzyme linked immunosorbent 
assay (ELISA) test (Abbott Diagnostics, Tokyo, Japan). The 
test is an immuno-chromatographic test for the qualitative and 
differential diagnosis of HIV 1 and 2 in human serum. All ini-
tially positive tests were confirmed using Immunocomb HIV 1 
and 2 kits (Orgenics, Yavne, Israel). CD4 lymphocyte count 
was carried out on the EDTA anticoagulated sample using the 
Dynal beads method (Invitrogen, Carlsbad, CA). This method 
is an alternative method to flow cytometry for the enumeration 
of peripheral CD4 lymphocyte in resource-limited settings. 
The Dynal beads technique uses paramagnetic polymer 
beads coated with anti CD4 monoclonal antibodies (mAbs) 
to capture and isolate CD4 T-lymphocyte from whole blood. 
Previous study indicated that CD4 count from Dynal beads 
method correlated positively and significantly with values 
from flow cytometry (r = 0.90).9
Statistical analysis
Data was analyzed using a Statistical Package for Social 
Sciences version 10 (SPSS Inc, Chicago IL USA). Results 
was expressed as mean and standard deviation. Differences 
in prevalence of HIV for demographics (age, sex and marital 
status) variables among TB-infected subjects were tested for 
significance by chi square analysis. A P-value of 0.05 was 
considered significant in all statistical comparisons.
Results
Of the 120 TB patient tested for HIV, 30 (25%) were 
positive. HIV prevalence was higher in females 24 (80%) 
when compared to males 6 (20%) as well as among 
singles (66.7%) as compared to married patients (33.3%) 
(χ2 = 83.5 and χ2 = 126.2 respectively P = 0.001). HIV 
prevalence was significantly higher in subjects in the 38–47 
and 28–37 years age groups (both 40%) followed by the 
18–28 years age group (20%) (χ2 = 42.6, P = 0.04). The 
mean CD4 lymphocyte count of the HIV-infected subjects 
was significantly lower (P = 0.001) (195 ± 40.5 cells/µL) 
compared to the non-HIV-infected (288 ± 35.25 cells/µL). 
HIV 1 was the predominant viral subtype. Table 1 shows 
the distribution of HIV serological prevalence among TB 
infected patients based on age, gender and marital status.HIV/AIDS - Research and Palliative Care 2010:2 
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Discussion
There is variable information concerning the prevalence 
of HIV among TB-infected patients in the Nigerian popu-
lation. In this study we observed a 25% HIV prevalence 
among adult TB patients. This finding is in agreement with 
previous reports in Nguru in the North eastern Nigeria.10 
Similarly out of 59 patients with pulmonary TB studied in 
Kampala, Uganda,11 two-thirds of the patients were HIV-
seropositive. Similarly in Sagamu, Nigeria Daniel and 
colleagues12 observed a 14.9% HIV prevalence amongst 
their cohort of TB infected patients. Of patients with 
confirmed pulmonary TB in Zambia, 49% were positive 
for HIV.13 Studies among TB patients in Kenya14 observed 
40.7% prevalence while nearly 40% of the smear-positive 
TB patients in Tanzania were attributable to HIV.15 However, 
out of 13,269 patients diagnosed with TB in the Netherlands 
who were then tested for HIV between 1993 to 2001, 
542 were HIV positive (4.1%).16 Among 184 newly diag-
nosed TB patients tested for HIV in Singapore, 15 (8.2%) 
was seropositive.6
For many years; the efforts to tackle TB and HIV have 
been largely separate, despite the overlapping epidemiology. 
However, it is now increasingly recognized that only through 
combined and coordinated efforts for both TB and HIV 
can this dual epidemic be halted. There is an increasingly 
alarming trend in the overall incidence of TB across the 
globe. While several regions seem to be experiencing declines 
in TB incidence, there is a dramatic increase in Africa. 
HIV-positive individuals are at greater risk of contracting 
such opportunistic infections such as TB, and treatment for 
co-infected patients is complicated by interactions between 
prescribed drugs. Furthermore, TB control efforts have 
been hampered in countries that are overwhelmed by the 
HIV/AIDS epidemic.
The mean CD4 lymphocyte count of the HIV-infected 
TB subjects was significantly lower (P = 0.01) (195 ± 
40.5 cells/µL) compared to counts for the non HIV-infected 
(288 ± 35.25 cells/µL). In several studies of HIV infected 
patients with pulmonary TB, the median CD4 T-cell count 
was 300 cells/µL.17 Until 1993, two clinical presentations 
of TB/HIV co-infection were recognized; TB in the HIV-
seropositive patients without AIDS and TB accompanied by 
AIDS.18 Subsequently, the World Health Organization classified 
TB as an AIDS defining condition in HIV infected patients.19 
The CD4 lymphocyte count, which defines the degree of 
immunosuppression, is used to compare the clinical radiologi-
cal presentations.20 The CD4 lymphocyte count cut-off point 
has been defined as 200 cells/µL. Studies have shown that the 
primary progressive form of TB predominates in patients with 
CD4 counts 200 cells/µL.20 Although TB can be a relatively 
early manifestation of HIV-1 infection, it is important to note 
that the risk of developing TB, and of disseminated infection, 
increases as the CD4 T-cell count decreases.
In this study, we observed a higher HIV prevalence 
rate among females (80%) as compared to males (20%). 
This higher incidence rate found within the women of this 
study parallels data observed in sub-Saharan Africa21 and 
of other parts of the world14 which estimated there were 
12 to 13 infected women for every infected man. Biological, 
cultural and socio-economic factors contribute to women’s 
greater vulnerability to HIV/AIDS. Women are four times 
more at risk of becoming infected with HIV during unpro-
tected vaginal intercourse than men. The vagina’s large 
surface area of susceptible tissue and micro trauma during 
intercourse makes women more physiologically vulnerable.22 
The synergy between HIV and other sexually transmitted 
infections (STIs) is another biological factor that makes 
women more vulnerable. Socio economic factors including 
women’s lack of access to education or personal income per-
petuate women’s lower status. Moreover widespread poverty 
drives some women into commercial sex work. Cultural 
traditions such as forced marriage, female genital mutilation 
and older men’s preference for younger women contribute to 
the observed increased female vulnerability to HIV .23
A significantly high HIV prevalence rate was observed 
among subjects in the 28–37 and 38–47 year age groups 
followed by those less than 20 years. This is in agreement 
with previous reports11,12 which found the highest HIV 
seropositive rate among patients aged between 30 to 
39 years (10.6%).
Table  Distribution of HIV serological prevalence among TB 
patients based on age, gender and marital status
Variable  Number 
tested
Number (%)  
HIV positive
χ  P-value 
Age (years)
18–27 54 6 (20) 42.6 0.04
28–37 48 12 (40)
38–47 12 12 (40)
48–57 6 0 (0)
Gender
Male 36 6 (20) 83.5 0.001
Female 84 24 (80)
Marital status
Married 78 10 (33.6) 126.2 0.001
Single 42 20 (66.7)    HIV/AIDS - Research and Palliative Care 2010:2 
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In this study we found HIV-1 as the predominant viral 
subtype responsible for HIV infection in TB infected patients 
in Port Harcourt, Nigeria. This finding is consistent with studies 
in other parts of Africa which found HIV-1 the predominant 
viral subtype.24–26 Never the less HIV-2 infection has been 
detected in other studies amongst African poulations.27,28
HIV prevalence was significantly higher among singles 
compared to married subjects. This finding is also consistent 
with previous reports29,30 which found single, unmarried 
persons more vulnerable to HIV infection. Single unmarried 
persons are more likely to maintain multiple sex partners or 
be involved in high risk sexual behaviors (homosexuality, 
commercial sex work, alcohol use and intravenous drug 
abuse) that make them vulnerable to infection with HIV. 
In the United States, a previous study has shown that people 
who use alcohol, tobacco, and other drugs are at a high risk 
for HIV infection.31 Both casual and chronic substance users 
are more likely to engage in high-risk behaviors such as 
unprotected sex, when they are under the influence of drugs 
or alcohol.32 Research conducted throughout sub-Saharan 
Africa has found close associations between alcohol use, 
risk taking sexual behavior, sexually transmitted infections 
and HIV infection.33
This study, has established the prevalence of human 
immunodeficiency virus infection among TB infected 
patients in Port Harcourt, Nigeria, and shows that a 
close link exists between active TB and HIV infection. 
We recommend that there be strict compliance to the Centers 
for Disease Control and Prevention (CDC) recommendation 
that all newly diagnosed TB patients be tested for HIV 
after counseling. Reactivation of TB among people living 
with HIV can be reduced by TB preventive therapy and by 
universal access to antiretroviral therapy.
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